Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients
space
 arrow  Summary for Patients (PDF)
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Simon, J. A.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

ARTICLE

Effect of Estrogen plus Progestin on Risk for Biliary Tract Surgery in Postmenopausal Women with Coronary Artery Disease: The Heart and Estrogen/progestin Replacement Study

right arrow Joel A. Simon, MD, MPH; Donald B. Hunninghake, MD; Sanjay K. Agarwal, MD; Feng Lin, MS; Jane A. Cauley, DrPH; Christine C. Ireland, MPH; James H. Pickar, MD, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group

2 October 2001 | Volume 135 Issue 7 | Pages 493-501

Background: Animal and observational epidemiologic studies have reported that estrogens may increase the risk for gallstones. No major clinical trials have examined the effect of estrogen plus progestin therapy in postmenopausal women on the risk for biliary tract surgery.

Objective: To determine the effect of estrogen plus progestin on the risk for biliary tract surgery in postmenopausal women with known coronary artery disease.

Design: Randomized, double-blind placebo-controlled trial of postmenopausal hormone therapy for coronary heart disease.

Setting: 20 U.S. clinical centers.

Participants: 2253 postmenopausal women with a gallbladder, 44 to 79 years of age at baseline, in the Heart and Estrogen/progestin Replacement Study (HERS).

Intervention: Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, daily in one tablet or identical placebo.

Measurements: Documented biliary tract surgery.

Results: A total of 147 women (7%) were hospitalized for biliary tract surgery in HERS. Treatment with estrogen plus progestin resulted in a marginally significant 38% increase in the relative risk for biliary tract surgery (P = 0.05). A small absolute difference in risk suggested that for every 185 women treated with estrogen plus progestin, one additional woman had biliary tract surgery per year. After adjustment for baseline and in-study statin use, the association was attenuated further (P = 0.09). After adjustment for treatment assignment and other variables, increased body mass index, fibric acid use, and a history of nonsurgical gallbladder disease were associated with an increased risk for biliary tract surgery, whereas statin use was associated with a decreased risk (for each comparison, P < 0.05).

Conclusion: Estrogen plus progestin therapy among postmenopausal women with known coronary disease resulted in a marginally significant increase in the risk for biliary tract surgery.

Author and Article Information
space

From Veterans Affairs Medical Center, San Francisco, and University of California, San Francisco, School of Medicine, San Francisco, California; Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, California; University of Minnesota School of Medicine, Minneapolis, Minnesota; Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania; and Wyeth-Ayerst Research, Radnor, Pennsylvania.

Disclosures: Dr. Picker is a full-time salaried employee of Wyeth-Ayerst Research; all other authors received research support (for most authors, specifically for work on the HERS trial) from Wyeth-Ayerst Research. Dr. Agarwal is a speaker for Wyeth-Ayerst Research and for Pfizer, Inc. Dr. Simon has received donations (for research on vitamin C) from Roche Vitamins, Inc., and is a member of the scientific advisory committee to the California Walnut Marketing Board. Dr. Cauley has received research support from Roche Pharmaceuticals, honoraria from Proctor & Gamble, and both research support and honoraria from Eli Lilly and Co. and Merck & Co., Inc.

Acknowledgments: The authors thank Josephine Fong, MS, for help with the initial data analyses and Eric Vittinghoff, PhD, for assistance in developing the statistical approaches used in the final analyses.

Grant Support: By Wyeth-Ayerst Laboratories.

Requests for Single Reprints: Joel A. Simon, MD, MPH, General Internal Medicine Section (111A1), San Francisco Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, California 94121; e-mail, jasimon{at}itsa.ucsf.edu.

Current Author Addresses: Dr. Simon: General Internal Medicine Section (111A1), Medical Service, Veterans Affairs Medical Center, San Francisco, CA 94121.

Dr. Hunninghake: Heart Disease Prevention Clinic, Box 192, 151 Variety Club Heart and Research Center, 401 East River Parkway, Minneapolis, MN 55455.

Dr. Agarwal: Department of Obstetrics and Gynecology, Burns and Allen Research Institute, Cedars-Sinai Medical Center, 8635 West 3rd Street, Suite 160, Los Angeles, CA 90048.

Ms. Lin and Ms. Ireland: Prevention Sciences Group, Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, 74 New Montgomery Street, Suite 600, San Francisco, CA 94105.

Dr. Cauley: Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, 130 DeSoto Street, Pittsburgh, PA 15261.

Dr. Pickar: Wyeth-Ayerst Research, Box 42528, Philadelphia, PA 19101.

Author Contributions: Conception and design: J.A. Simon.

Analysis and interpretation of the data: J.A. Simon, D.B. Hunninghake, S.K. Agarwal, J.H. Pickar.

Drafting of the article: J.A. Simon, D.B. Hunninghake, S.K. Agarwal, J.H. Pickar.

Critical revision of the article for important intellectual content: J.A. Simon, S.K. Agarwal, J.A. Cauley, C.C. Ireland.

Final approval of the article: J.A. Simon, D.B. Hunninghake, F. Lin, J.A. Cauley.

Provision of study materials or patients: D.B. Hunninghake, S.K. Agarwal.

Statistical expertise: F. Lin.

Administrative, technical, or logistic support: C.C. Ireland.

Collection and assembly of data: S.K. Agarwal, J.A. Cauley.


Related articles in Annals:

Summaries for Patients
Hormone Replacement Therapy in Postmenopausal Women with Heart Disease and Risk for Gallstones That Require Surgery
Annals 2001 135: S44. [Full Text]  



This article has been cited by other articles:


Home page
BMJHome page
B. Liu, V. Beral, A. Balkwill, J. Green, S. Sweetland, G. Reeves, and for the Million Women Study Collaborators
Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study
BMJ, July 10, 2008; 337(jul10_2): a386 - a386.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
H. H. Wang, N. H. Afdhal, and D. Q-H. Wang
Overexpression of estrogen receptor {alpha} increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice
J. Lipid Res., April 1, 2006; 47(4): 778 - 786.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
U.S. Preventive Services Task Force*
Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women: Recommendations from the U.S. Preventive Services Task Force
Ann Intern Med, May 17, 2005; 142(10): 855 - 860.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. J. Cirillo, R. B. Wallace, R. J. Rodabough, P. Greenland, A. Z. LaCroix, M. C. Limacher, and J. C. Larson
Effect of Estrogen Therapy on Gallbladder Disease
JAMA, January 19, 2005; 293(3): 330 - 339.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
D. Grady, B. Ettinger, E. Moscarelli, L. Plouffe Jr, S. Sarkar, A. Ciaccia, and S. Cummings
Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene Evaluation
Obstet. Gynecol., October 1, 2004; 104(4): 837 - 844.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
Cholecystitis, Biliary Tract Surgery, and Pancreatitis
Obstet. Gynecol., October 1, 2004; 104(4_suppl): 17S - 24S.
[Full Text] [PDF]


Home page
JAMAHome page
H. D. Nelson
Postmenopausal Estrogen for Treatment of Hot Flashes: Clinical Applications
JAMA, April 7, 2004; 291(13): 1621 - 1625.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
C. Minelli, K. R Abrams, A. J Sutton, and N. J Cooper
Benefits and harms associated with hormone replacement therapy: clinical decision analysis
BMJ, February 14, 2004; 328(7436): 371.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
U.S. Preventive Services Task Force*
Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Recommendations and Rationale
Ann Intern Med, November 19, 2002; 137(10): 834 - 839.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. Hulley, C. Furberg, E. Barrett-Connor, J. Cauley, D. Grady, W. Haskell, R. Knopp, M. Lowery, S. Satterfield, H. Schrott, et al.
Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)
JAMA, July 3, 2002; 288(1): 58 - 64.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. B. Petitti
Hormone Replacement Therapy for Prevention: More Evidence, More Pessimism
JAMA, July 3, 2002; 288(1): 99 - 101.
[Full Text] [PDF]


Home page
JAMAHome page
D. Grady
A 60-Year-Old Woman Trying to Discontinue Hormone Replacement Therapy
JAMA, April 24, 2002; 287(16): 2130 - 2137.
[Full Text] [PDF]


Home page
JAMAHome page
M. A. Hlatky, D. Boothroyd, E. Vittinghoff, P. Sharp, M. A. Whooley, and for the HERS Research Group
Quality-of-Life and Depressive Symptoms in Postmenopausal Women After Receiving Hormone Therapy: Results From the Heart and Estrogen/Progestin Replacement Study (HERS) Trial
JAMA, February 6, 2002; 287(5): 591 - 597.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
K. M. Rexrode and J. E. Manson
Postmenopausal Hormone Therapy and Quality of Life: No Cause for Celebration
JAMA, February 6, 2002; 287(5): 641 - 642.
[Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2001 by the American College of Physicians.